Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Company to Host Conference Call on Wednesday, August 3, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , July 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2022 after the market closes on August 3, 2022.

Nevro to Report Second Quarter 2022 Financial Results

High-Frequency 10 kHz Therapy Provided Substantial and Durable Pain Relief, Improved Health-Related Quality of Life, Better Sleep Quality and Neurologic Improvements Over 12 Months   REDWOOD CITY, Calif. , July 5, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the complete 12-month results from the SENZA-PDN Randomized Controlled Trial (RCT), including health-related quality of life (HRQoL) outcomes in patients with Painful Diabetic Neuropathy (PDN) treated with high-frequency 10 kHz spinal cord stimulation (SCS), were published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulation Therapy

Nevro is the top pure play spinal cord stimulation [SCS] company with three major industry competitors. Nevro's recent FDA approvals for its high frequency SCS system in treatment of painful diabetic neuropathy and non-surgical refractory back pain are game changers.

Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery

SENZA-PDN Randomized Controlled Trial Results From Original 10 kHz Arm Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 24-Months Follow-Up REDWOOD CITY, Calif. , June 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced  the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions supporting the use of 10 kHz spinal cord stimulation (SCS) therapy for patients with chronic pain, including results from the SENZA Painful Diabetic Neuropathy (PDN) randomized controlled trial (RCT).

Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy

Poster Presentation to Include 24-Month Follow-Up Results from Original 10 kHz Arm of SENZA-PDN Randomized Controlled Trial SENZA-PDN Study Results Selected to be Featured in ADA's Official Press Program Company to Participate in ADA's Product Theater Presentation REDWOOD CITY, Calif. , May 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, will be presented at the American Diabetes Association (ADA) 82nd Scientific Sessions to be held June 3-7, 2022 in New Orleans, LA.

Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.

Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat

Nevro Corp. (NYSE:NVRO ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Calvin Chu - Morgan Stanley Simran Kaur - Piper Sandler Robbie Marcus - JPMorgan Danielle Antalffy - SVB Securities Joanne Wuensch - Citi Suraj Kalia - Oppenheimer David Rescott - Truist Securities Maggie Boeye - William Blair Operator Good afternoon. My name is Chris, and I'll be your conference operator today.

Nevro Corp. (NVRO) CEO Keith Grossman on Q1 2022 Results - Earnings Call Transcript

REDWOOD CITY, Calif. , May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the first quarter ended March 31, 2022, provided guidance for the second quarter of 2022 and reiterated its full-year 2022 revenue guidance.

Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for

Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , April 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2022 after the market closes on May 4, 2022.

Nevro to Report First Quarter 2022 Financial Results

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.

Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage

REDWOOD CITY, Calif., March 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Noridian, the Medicare Administrative Contractor (MAC) that oversees the majority of the western United States, released an update to their Local Coverage Billing and Coding article (A57791 and A57792) for spinal cord stimulators for chronic pain to include two new ICD-10 codes that cover Painful Diabetic Neuropathy (PDN).

Nevro Announces Positive Medicare Coverage Update from Noridian for the Treatment of Painful Diabetic Neuropathy

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

Nevro Corp.'s (NVRO) CEO Keith Grossman on Q4 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full-year ended December 31, 2021 and provided guidance for the first quarter and full-year of 2022.

Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance

REDWOOD CITY, Calif., Feb. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D.

Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series

REDWOOD CITY, Calif., Feb. 11, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced 12-month data from the SENZA-NSRBP randomized controlled trial (RCT) was published online in Journal of Neurosurgery: Spine.1 These data show that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients compared to Conventional Medical Management (CMM).

Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine

REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at Citi's 2022 Virtual Healthcare Conference

REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI).

Nevro Named to 2022 Bloomberg Gender-Equality Index

REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN).

Nevro Responds to Competitor's Announcement of FDA Approval for Painful Diabetic Neuropathy

REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market closes on February 23, 2022.

Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results

Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP).

Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)

REDWOOD CITY, Calif., Jan. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced  the results from data presentations at the 2022 North American Neuromodulation Society (NANS) Annual Meeting supporting the use of 10 kHz spinal cord stimulation (SCS) therapy for patients with chronic pain, including results from the SENZA Painful Diabetic Neuropathy (PDN) and SENZA Non-Surgical Refractory Back Pain (NSRBP) randomized clinical trials (RCT).

Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy

News for Nevro Stock (NVRO)